Unlearn.AI Closes On $12M To Improve Clinical Trials

It is often difficult to find enough patients for clinical trials.

So San Francisco-based Unlearn developed DiGenesis, a machine-learning platform that generates control patient data for clinical studies. Now the company has secured a $12 million Series A financing.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Embracing Innovation to Move Forward

Podcasts

Your Digital Twin - UnlearnAI

Podcasts

Using AI Digital Twins for Drug Testing

Dr. Charles Fisher, CEO of Unlearn AI, discusses creating digital clones by using artificial intelligence for use in clinical drug trials.
A fascinating approach to the problem of how to make clinical trials more efficient, and understand more about what may be possible with more and better patient data.
At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.